Updates
MedWatch: The FDA Safety Information and Adverse Event Reporting Program
The FDA’s medical product safety reporting program for health professionals, patients and consumers. MedWatch receives reports from the public and when appropriate, publishes safety alerts for FDA-regulated products. The most recent alerts/recalls are:
Consumer Updates
Where and How to Dispose of Unused Medicines
 Is your medicine cabinet full of expired drugs or medications you no longer use? The best way to dispose of most types of expired, unwanted or unused medicines is through a drug take-back program.
Guidance Documents
View all Official FDA Guidance Documents and other Regulatory Guidance
You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period.
Webinars and Virtual Workshops
Implementing FDA’s IVPT Guidance Recommendations: A Step-By-Step Illustration - Workshop
April 29 - 30, 2025
Day 1: Tue, Apr 29; 8:30 a.m. - 5:30 p.m. ET
-
Day 2: Wed, Apr 30; 8:30 a.m. - 3:30 p.m. ET
-
The In Vitro Permeation Test (IVPT) is an important performance test used by the generic drug industry to support demonstrations of bioequivalence for generic topical drug products, when utilizing efficient characterization-based bioequivalence approaches. The workshop will clarify the intent of FDA recommendations for IVPT studies, with step-by-step demonstrations illustrating how IVPT study procedures can be performed in a manner compatible with recommendations in FDA’s Guidance for Industry.
UPDATED MEETING DATE AND PUBLIC PARTICIPATION INFORMATION: May 5, 2025 Joint Meeting of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee Meeting Announcement
Mon, May 5, 2025; 8:00 a.m. - 5:00 p.m. ET
The Committees will discuss the findings of the completed ER/LA OA PMRs 3033-1 and 3033-2 (link to Release and Reissue letter). These PMRs are prospective (3033-1) and retrospective (3033-2) epidemiologic studies that examined the serious risks and predictors of misuse, abuse, addiction, and fatal and non-fatal opioid overdose in patients with long-term use of opioid analgesics for management of chronic pain, including patients prescribed ER/LA OAs.
Registration is not necessary.
View Upcoming FDA Meetings, Conferences and Workshops
Public meetings involving the FDA: Upcoming events, past meetings, meeting materials, and transcripts
About Us
The Public Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, patients and patient advocacy organizations, consumer groups, trade associations, think tanks and academia, and other interested parties, in order to better inform our policy making process, identify policy hurdles or misconceptions, and create strategic collaborations. For more information, please contact us at PublicEngagement@fda.hhs.gov. For patient specific inquiries, please contact us at Patients Ask FDA.
Did someone forward you this email? Sign up below!
|
